Oncólogo molecularmente incorrecto. Círculos, cuadrados, linfocitos cabreados. Escribo una #novela. #melanoma #immunotherapy #genetics. Opinions are my own!😇
Joined November 2012
- Tweets9.1K
- Following1.4K
- Followers2.2K
- Likes5K
Pinned Tweet
Happy to share the final results of the 🇪🇸 & 🇫🇷 ph2 trial of intratumoral BO-112 + pembro for patients with anti PD-1 resistant #melanoma. 25% ORR and 54% patients alive at 2 years. 16 years of basic and clinical research behind. Some context here 👇🧵
ascopubs.org/doi/10.1200/JCO…
Iván Márquez Rodas 🇪🇦 retweeted
de Adamuz, perdimos a Jesús Saldaña, residente de La Paz.
La SEC creó una beca con su nombre y hoy, al entregarla en #SEC26, la sala se ha levantado a aplaudir varios minutos.
Con Urda tan reciente, lo más emotivo del congreso de momento.
Iván Márquez Rodas 🇪🇦 retweeted
🚨 The congress may be over but the learning definitely isn’t!
The COMPLETE #ESMO26 Newsletter from @OncoAlert is OUT TODAY!!! Our faculty’s top trials, key takeaways and expert context from Madrid, all distilled into one read 📩
oncoalert.m-pages.com/nhMpwe…
Thousands of abstracts. One inbox. Zero excuses to miss the signal 😉
OUT TODAY!!
THE COMPLETE #ESMO26 NEWSLETTER 📰
Bringing together our top picks from the most important trials presented in Madrid, all in one email.
📩 Register to receive it: buff.ly/N5gYtAc
Curated by oncologists, for colleagues in cancer care, our mission is to make the latest oncology science accessible, relevant, and easy to digest.
We are OncoAlert 🚨 — For Colleagues, by Colleagues.
Best,
The OncoAlert Network
@cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3
Iván Márquez Rodas 🇪🇦 retweeted
e-highlights ESMO 2026 - Informe 3: Pósteres. groupgem.es/informes-esmo-2/
Iván Márquez Rodas 🇪🇦 retweeted
On top of that, Spanish oncology is world-class, not only in trial recruitment but also in investigator-initiated trials. Cooperative groups like @GrupoMelanoma @gecp_org @_SOLTI have been presenting practice-changing data in the oral sessions.
Also my disclousure: Spanish, but based outside Spain 😉
It is a shared opinion among many attendees that @myESMO gets the most out of its budget/worforce when the Annual Meeting is hosted in Spain (MAD/BCN)
I am sure there are sevral aspects that could be improved, and others that may never be fixed. However, venues, infrastructure, security, and transport hubs make these cities the best options for hosting the Annual Meeting in the long term, like Chicago for @ASCO
Other cities have also offered great experiences and could continue to host the 15+ other ESMO meetings/preceptorships/courses...
@FAndreMD @curijoey must have had this in mind several times
@IFEMA @Fira_Barcelona #ESMO26 #Oncology
@OncoAlert @brunolarvol @_SEOM
Iván Márquez Rodas 🇪🇦 retweeted
🔬 #ESMO26 | El Dr. @ivanpantic1980, portavoz de SEOM y presidente del @GrupoMelanoma, analiza INTerpath-001 (LBA1), presentado en la Sesión Presidencial de @myESMO 2026.
🧬 Primera fase III positiva de una terapia individualizada de neoantígenos basada en ARNm en melanoma #ESMO26
Iván Márquez Rodas 🇪🇦 retweeted
Thank you @ivanpantic1980
I am very happy you enjoyed it. It was indeed a out of the box idea - showing how we can learn, and moreover do cross-fertilization from other tumor areas, and an academic trial! Congratulations for the great effort.
Iván Márquez Rodas 🇪🇦 retweeted
Novedades en melanoma del #ESMO26. Empezamos con STARBOARD (fase 3): encorafenib + binimetinib + pembrolizumab vs pembrolizumab en 1L BRAF V600. SLP 33,0 vs 3,4 m (HR 0,33), ORR 70% vs 32,7%. Pero: 70% TRAE G≥3, 42,7% suspende BRAF/MEKi y brazo control discutible.
My personal take on the (again) NADINA up date: we cannot omit adjuvant therapy in near pCR; only in pCR #melanoma #ESMO2026 @GrupoMelanoma . Before making decisions from asumptions from small trials, we should think about how we translate them into confirmatory trials.
This is a great achievement for our @GrupoMelanoma In around 6m, the group managed to include all the patients, with an out of the box idea in one single country. Brilliant presentation by @g_develasco Thanks to @myESMO for selecting it & @TeresaSAmaral for her great discussion
🚨 #ESMO26 | PLUG-IN GEM 2301
Enfortumab vedotin + pembro in anti–PD-1–refractory advanced melanoma (N=60):
▪️ Confirmed ORR 25% | DCR 55%
• BRAF WT: ORR 21.4%
• BRAF-mut: ORR 33.3%
• Acral 33.3% | Mucosal 20.0% confirmed ORR
Safety with no new signals!
Interestingly, Nectin-4 expression did not identify responders….exploratory, but worth watching 🤔
A new ADC signal in refractory melanoma…this PLUG-IN deserves to stay connected 🔌
Congrats to @g_develasco and all the @GrupoMelanoma team! 👏🏼
@OncoAlert @OncoReporte @myESMO @_SEOM @GrupoMelanoma
RT @MarioBalsaMD: 🚨 #ESMO26 | PLUG-IN GEM 2301
Enfortumab vedotin + pembro in anti–PD-1–refractory advanced melanoma (N=60):
▪️ Confirmed…
Iván Márquez Rodas 🇪🇦 retweeted
🚨 One of the big melanoma moments of #ESMO26!
INTerpath-001 is positive, but the most interesting part may be the questions it opens:
1. Who benefits most?
2. Will the RFS benefit translate into OS?
3. And where does a personalized mRNA vaccine fit in the neoadjuvant era?
My #OAOnTheGo take 👇
@OncoAlert @myESMO @_SEOM @GrupoMelanoma
@hospitalclinic
#ClínicBarcelonaComprehensiveCancerCenter
🎥 #OAOnTheGO | OncoAlert at #ESMO26 Madrid
INTerpath-001 is positive! 🔬
@ProfGLongMIA @jasonlukemd
Dr. Mario Balsa (@HospitalClínic Barcelona) discusses pembrolizumab + personalized mRNA vaccine V940 in resected melanoma.
📊 2-year RFS: 82% vs 60% (HR 0.58)
📊 DMFS: 88.5% vs 80.2% (HR 0.62)
Will this translate into longer survival? Who benefits most? And how does it fit with neoadjuvant immunotherapy?
🎬 Watch now!
#Melanoma #OncoAlert
@DrBetofMDPhD, @cdanicas, @matteolambe, @NiuSanford, @GlopesMd, @PGrivasMDPhD, @brian_rini, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @DrYukselUrun, @Lucarecco, @mzugman, @HHorinouchi, @p_ciracimd, @DraMartinezLago, @DrVilmaPBarcia, @GIMedOnc, @MarioBalsaMD, @scocmem, @AmandaNizamMD, @GaiaGriguolo, @JankovicK, @Dr_Oncologista, @Erman_Akkus, @WeOncologists, @niklas_kluemper, @Markuseckstein
Iván Márquez Rodas 🇪🇦 retweeted
👑 Presidential #ESMO26! INTerpath-001: personalized mRNA vaccination reaches phase III in melanoma.
Resected stage IIB–IV melanoma, N=1,137: intismeran + pembrolizumab vs pembrolizumab.
💥 At 24 months:
• RFS: 82.2% vs 70.0% → HR 0.58
• DMFS: 88.5% vs 80.2% → HR 0.62
• Absolute gains: +12.2% RFS / +8.3% DMFS
• Benefit emerges mainly after 6 months
• Grade ≥3 AEs: 23.6% vs 20.3%
• OS still immature
A clinically meaningful new mechanism, but the real question now is positioning 🤔
For macroscopic stage III: adjuvant personalized vaccine after surgery, or neoadjuvant ipi/nivo before it? Biomarkers may ultimately decide.
Congrats to @ProfGLongMIA and all the team! 👏🏼
@OncoAlert
@OncoReporte @myESMO @_SEOM @GrupoMelanoma
These are the kind of reflections that appears after seing the data, and not based on speculations driven by casino-markets. Thank you for your sensible comment! @YannickBuccella
So the “not-so-official-anymore“ presentation is in: The melanoma vaccine works. We knew that, 82% recurrence-free at two years vs 70% with immunotherapy alone.
It's built individually for each patient, the logistics are enormous: Sequence their tumor, design the vaccine, manufacture it for one person. Weeks of work that will cost a fortune.
A treatment like that doesn't scale to most of the world. It scales to countries that can afford a factory run per patient. I live in a country which happens to be able to afford that, most countries can’t. Melanoma kills people everywhere. This will reach a fraction of them.
Solving cancer and solving access are two different problems. We just got better at the first one.
Iván Márquez Rodas 🇪🇦 retweeted
So the “not-so-official-anymore“ presentation is in: The melanoma vaccine works. We knew that, 82% recurrence-free at two years vs 70% with immunotherapy alone.
It's built individually for each patient, the logistics are enormous: Sequence their tumor, design the vaccine, manufacture it for one person. Weeks of work that will cost a fortune.
A treatment like that doesn't scale to most of the world. It scales to countries that can afford a factory run per patient. I live in a country which happens to be able to afford that, most countries can’t. Melanoma kills people everywhere. This will reach a fraction of them.
Solving cancer and solving access are two different problems. We just got better at the first one.
Iván Márquez Rodas 🇪🇦 retweeted
e-highlights ESMO 2026 - Día 1: Informe 1
groupgem.es/informes-esmo-2/
Aquí, de tranquis; a escuchar la plenaria, que me han dicho que no hay nada de polémica ni expectacióm alguna @GrupoMelanoma #melanoma @myESMO
